ENZASTIK 40

Indications

• Low blood volume
• Hypovolemic shock
• Burns
• Cardiopulmonary bypass

Dosage

Children: Initially 10-20 mL per kilogram. Adjust according to the patient's condition and response, using 3.5-4% solution. Use under specialist supervision to mitigate the risk of fluid overload.

Adults: Dose according to requirements, typically administered intravenously. Consult product literature for specific dosing guidance.

Mechanism of action

Gelatin acts as a plasma expander by increasing the oncotic pressure in the vascular compartment, which helps to retain fluid within the bloodstream and restore circulating blood volume. This mechanism aids in maintaining blood pressure and improving tissue perfusion.

Pharmacodynamics

Gelatin solutions increase blood volume and improve hemodynamic stability in patients experiencing hypovolemic conditions. By drawing water into the vascular space, they help to counteract the effects of low blood volume, such as hypotension and compromised organ perfusion.

Pharmacokinetics

Gelatin is administered intravenously, and its effects can be observed relatively quickly. The half-life and the metabolic clearance depend on the formulation and concentration of the solution. Gelatin is gradually metabolized by macrophages and eliminated by the renal system. Close monitoring of fluid balance is essential, particularly in patients with cardiac or renal impairment.

Contra-indications

• Severe liver disease
• History of circulatory disease
• Severe cardiac disease

Adverse effects

• Fever
• Flushing
• Nausea
• Urticaria
• Rare or very rare shock

Interactions

• Calcium salts

Precautions

• Monitor cardiovascular and respiratory function
• Correct dehydration when administering
• Administer slowly to avoid rapid rise in blood pressure and cardiac failure
• Increased capillary permeability

Pregnancy

Consult product literature for specific guidance regarding use in pregnancy.

Breast-feeding

Consult product literature for specific guidance regarding use in breastfeeding.

Storage

Store at controlled room temperature, protect from light. Refer to product-specific storage instructions.

Formulations

• 5% solution for infusion
• 20% solution for infusion
• Concentrated solution (15-25% protein)
• Isotonic solution (3.5-5% protein)

Indications

• Metastatic hormone-relapsed prostate cancer
• Castration-resistant prostate cancer
• Hormone-sensitive prostate cancer

Dosage

Adults: The usual dose for adults is 160 mg taken orally once daily. In patients with moderate to severe hepatic impairment, the initial dose may need to be reduced to 300 mg twice daily.

Mechanism of action

Enzalutamide competitively inhibits androgen receptors (AR) with a binding affinity 5 to 8 times greater than first-generation antiandrogens like bicalutamide. It prevents androgen binding, inhibits AR nuclear translocation, and blocks interaction with chromosomal DNA, disrupting oncogene upregulation. This multi-faceted inhibition effectively reduces prostate cancer cell growth and induces apoptosis.

Pharmacodynamics

Enzalutamide exerts its effects by blocking AR activity, which is pivotal in the progression of prostate cancer. While it is effective in the initial stages of treatment, resistance can develop due to mutations in the AR. Clinical studies have shown that enzalutamide reduces serum prostate-specific antigen (PSA) levels significantly and decreases overall mortality risk in patients compared to placebo.

Pharmacokinetics

Enzalutamide is administered orally and has a high oral bioavailability. It is extensively metabolized in the liver, primarily through CYP2C8 and CYP3A4 pathways. The half-life of enzalutamide is approximately 5.8 days, allowing for once-daily dosing. It is important to monitor liver function, particularly in patients with hepatic impairment.

Mechanism of action

Anisole acts as a substrate in various biochemical pathways, particularly as a precursor in the synthesis of methoxy-substituted aromatic compounds. It may exhibit effects through modulation of neurotransmitter systems, although specific mechanisms related to therapeutic use are less well-defined.

Pharmacodynamics

Anisole's pharmacodynamic properties are largely based on its chemical structure, which allows it to interact with various biological targets. It may influence enzyme activity and alter metabolic pathways, particularly those involving aromatic compounds. Its effects are dose-dependent and can vary based on the specific application and formulation.

Pharmacokinetics

Anisole is absorbed through the gastrointestinal tract and can be metabolized in the liver through various enzymatic processes. Its elimination half-life and route of excretion can vary based on individual metabolic factors. The primary metabolic pathways include oxidation and conjugation, leading to the formation of various metabolites that are excreted primarily in urine.

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Anisole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether anisole is excreted in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store in a tightly closed container in a cool, dry place away from incompatible substances.

Formulations

• {'formulation': 'Anisole', 'molecular_formula': 'C7H8O'}

Dosage

Children: Refer to specific guidelines or literature for dosing information.

Adults: Refer to specific guidelines or literature for dosing information.

Pregnancy

Consult healthcare professionals before use. Safety during pregnancy is not well established.

Breast-feeding

Consult healthcare professionals before use. Safety during breastfeeding is not well established.

Storage

Store in a cool, dry place away from direct sunlight.

Dosage

Children: Refer to specific formulations and usages, as dosing can vary widely depending on the application and regulatory guidelines.

Adults: Refer to specific formulations and usages, as dosing can vary widely depending on the application and regulatory guidelines.

Mechanism of action

Butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) act as antioxidants by inhibiting the oxidation of lipids. They scavenge free radicals and donate hydrogen atoms to reactive species, thus stabilizing and preventing oxidative damage to cellular components. This action helps to protect the integrity of cell membranes and prevent the formation of harmful peroxides.

Pharmacodynamics

The pharmacodynamic properties of butylated compounds are primarily related to their antioxidant activity. They exhibit a dose-dependent ability to inhibit lipid peroxidation, which is crucial in protecting cells from oxidative stress. Furthermore, they may modulate certain biochemical pathways involved in cell signaling and apoptosis, although these effects are less well-characterized.

Pharmacokinetics

Butylated compounds are absorbed from the gastrointestinal tract following oral ingestion. They undergo metabolic processing primarily in the liver, where they are conjugated and excreted in urine. The half-life of butylated compounds in humans is variable, influenced by factors such as dosage and individual metabolism. Accumulation in tissues is generally low, but prolonged exposure may lead to higher tissue concentrations.

Adverse effects

• Gastrointestinal disturbances
• Allergic reactions
• Potential carcinogenic effects with prolonged exposure

Precautions

• Use with caution in patients with a history of hypersensitivity to butylated compounds
• Avoid prolonged exposure due to potential toxicity

Pregnancy

Limited data available, use only if the benefits outweigh the risks.

Breast-feeding

Unknown, exercise caution and consult a healthcare provider.

Storage

Store in a cool, dry place away from light.

Formulations

• Butylated hydroxytoluene (BHT)
• Butylated hydroxyanisole (BHA)

Indications

• Food preservative
• Antioxidant in cosmetics and pharmaceuticals
• Research on oxidative stress

Dosage

Children: Refer to BNF for Children for specific pediatric dosing information.

Adults: Refer to BNF for specific dosing guidelines as it varies based on the formulation and intended use.

Mechanism of action

BHT exhibits a pro-oxidative effect as a phenolic antioxidant, particularly in the presence of initiators like paraquat. It has been shown to chemically donate electrons to paraquat, leading to the generation of reactive oxygen species, which can result in chromosomal damage. This mechanism involves the reduction of paraquat cation to paraquat monocation radical and the subsequent accumulation of oxidative stress in cells.

Pharmacodynamics

As an antioxidant, BHT primarily functions by disrupting lipid peroxidation processes, protecting cellular components from oxidative damage. However, its pro-oxidative actions in combination with certain chemicals may lead to increased oxidative stress and cytotoxicity. The dual role of BHT as both an antioxidant and a pro-oxidant complicates its pharmacodynamic profile, particularly in the context of its interactions with other substances.

Pharmacokinetics

BHT is absorbed in the gastrointestinal tract when ingested, and it is metabolized in the liver. The elimination half-life and metabolic pathways of BHT are not extensively documented, but it is known to undergo biotransformation to various metabolites. The distribution in body tissues can vary based on the dosage and individual metabolism, and it is excreted primarily through urine and feces.

Pregnancy

There are limited data on the use of butylhydroxytoluene (BHT) in pregnancy. It is advised to use caution and consult healthcare professionals before use.

Breast-feeding

Limited information is available regarding the excretion of butylhydroxytoluene in human milk. Caution is recommended when considering use during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Keep container tightly closed.

Formulations

• Food additive
• Cosmetic ingredient

Indications

• Supplementation in ketogenic diets
• Energy source for athletes
• Potential aid in weight management
• Cosmetic applications as an emollient and skin conditioning agent

Dosage

Children: Refer to specific guidelines or product instructions, as

Adults: Refer to specific guidelines or product instructions, as dosing can vary based on intended use.

Mechanism of action

Caprylocaproylca is metabolized in the liver, where it is rapidly converted into ketones, providing a quick source of energy. This process occurs through beta-oxidation, where the fatty acids are broken down into acetyl-CoA, leading to the production of ketone bodies. These ketone bodies can be utilized by various tissues, including the brain, as an alternative energy source to glucose.

Pharmacodynamics

Due to its structure as a medium-chain fatty acid, caprylocaproylca is absorbed more rapidly than long-chain fatty acids, leading to a quick increase in serum ketone levels. This can be particularly beneficial in ketogenic diets, where the aim is to maintain a state of ketosis. The energy derived from caprylic and capric acids can help improve physical performance and reduce feelings of hunger, making it useful in weight management strategies.

Pharmacokinetics

Caprylocaproylca has a rapid absorption profile due to its medium-chain triglyceride composition. After ingestion, it is transported directly to the liver via the portal vein, bypassing the lymphatic system, which is typical for long-chain triglycerides. This leads to a quicker onset of energy availability. The half-life and elimination of caprylic and capric acids can vary based on individual metabolism and dietary factors, but they are generally metabolized efficiently, resulting in minimal accumulation in the body.

Pregnancy

Information regarding the safety of caprylocaproylca during pregnancy is limited. It is advisable to consult a healthcare provider before use.

Breast-feeding

The safety of caprylocaproylca during breastfeeding has not been well studied. Caution is recommended, and consultation with a healthcare professional is advised.

Storage

Store in a cool, dry place away from direct sunlight. Ensure that it is kept out of reach of children.

Indications

• Monitoring respiratory function
• Assessment of metabolic status
• Management of respiratory acidosis
• Management of respiratory alkalosis

Dosage

Children: Dosing for interventions related to carbon dioxide levels in pediatric patients should be guided by clinical protocols and the BNF for Children.

Adults: Dosing for interventions related to carbon dioxide levels is typically based on clinical assessment and individual patient needs. Refer to clinical guidelines for specific scenarios.

Mechanism of action

Carbon dioxide acts primarily as a signaling molecule in the body, influencing respiratory drive and blood pH. It is produced during cellular respiration and is a critical component of the bicarbonate buffering system, which helps maintain acid-base homeostasis. Elevated levels of CO2 in the blood stimulate ventilation in the lungs, increasing the rate of gas exchange and facilitating the removal of excess CO2.

Pharmacodynamics

The pharmacodynamic effects of dioxides, particularly carbon dioxide, are closely related to its concentration in the blood. As CO2 levels increase, it leads to respiratory acidosis, which can stimulate the respiratory centers in the brain to increase ventilation. Conversely, low levels of CO2 can cause respiratory alkalosis, potentially leading to decreased respiratory drive. CO2 also plays a role in vasodilation and can affect blood flow and pressure through its influence on smooth muscle tone.

Pharmacokinetics

Carbon dioxide is produced endogenously during metabolic processes and is transported in the bloodstream primarily in three forms: dissolved in plasma, as bicarbonate ions (HCO3-), and bound to hemoglobin. The half-life of CO2 in the bloodstream is very short due to its rapid exchange with alveolar gas in the lungs. The elimination of CO2 occurs through exhalation, making it a dynamic component of respiratory physiology.

Pregnancy

Data on the effects of dioxide during pregnancy are limited. Caution is advised due to potential risks associated with exposure.

Breast-feeding

Limited data are available regarding the excretion of dioxide in human milk. Caution is recommended.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Indications

• Constipation
• Decreased intraocular pressure

Dosage

Children: For children, refer to the BNF for Children for appropriate glycerin dosing guidelines.

Adults: For constipation, glycerin can be administered rectally as a suppository. Follow specific product guidelines for dosage.

Mechanism of action

When administered rectally, glycerine exerts a hygroscopic and/or local irritant action, drawing water from the tissues into the feces and reflexively stimulating evacuation. Additionally, glycerine decreases intraocular pressure by creating an osmotic gradient between the blood and intraocular fluid, leading to fluid movement out of the aqueous and vitreous humors into the bloodstream.

Pharmacodynamics

Glycerine is commonly classified as an osmotic laxative but may also exert local irritant effects, lubricating, and fecal softening actions. Its onset of action typically occurs within 15 to 30 minutes when used as a suppository.

Pharmacokinetics

Glycerine is readily absorbed and metabolized in the body. It undergoes glycerol metabolism pathways, contributing to various biochemical processes including phospholipid biosynthesis. The pharmacokinetic profile of glycerine indicates a rapid onset of action due to its osmotic properties.

Adverse effects

• Abdominal cramps
• Diarrhea
• Nausea
• Vomiting
• Electrolyte imbalance

Precautions

• Use with caution in patients with renal impairment
• May cause dehydration if used excessively
• Monitor for electrolyte disturbances in prolonged use

Pregnancy

Glycerin is generally considered safe to use during pregnancy for indicated conditions. Always consult a healthcare provider before use.

Breast-feeding

Glycerin is unlikely to be harmful in breastfeeding mothers. Consult a healthcare provider for specific guidance.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• Suppositories
• Oral solution

Indications

• Anxiety disorders
• Nausea and vomiting
• Allergic conditions
• Preoperative sedation
• Pruritus

Dosage

Children: Refer to the BNF for Children for appropriate dosing recommendations based on age and weight.

Adults: Refer to the BNF for specific dosing guidelines based on the indication and patient characteristics.

Mechanism of action

Hydroxyzine works by antagonizing the H1 histamine receptors, leading to a reduction in the effects of histamine in the body. This action helps alleviate symptoms of allergic reactions and promotes sedation. Additionally, it may exert effects on serotonin and adrenergic receptors, which could contribute to its anxiolytic properties. Hydroxyzine is also involved in various metabolic pathways, including selenium metabolism and the degradation of reactive oxygen species.

Pharmacodynamics

The pharmacodynamic effects of hydroxyzine include sedation, anxiolysis, and reduction of allergic symptoms. Its sedative effects can make it useful in managing anxiety and inducing sleep, while its antihistaminic properties help to relieve symptoms such as itching and rashes associated with allergic reactions. The onset of action is typically within 15 to 30 minutes when taken orally, with peak effects occurring within 1 to 2 hours.

Pharmacokinetics

Hydroxyzine is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring approximately 2 hours after oral administration. It is extensively metabolized in the liver, with metabolites, including cetirizine, possessing their own therapeutic effects. Hydroxyzine has a half-life of approximately 20 hours, allowing for once or twice daily dosing. It is primarily excreted in the urine, with less than 1% of the unchanged drug found in urine.

Interactions

• hydroxyzine+antiepileptics: Severe (increases risk of overheating and dehydration)
• hydroxyzine+zonisamide: Severe (increases risk of overheating and dehydration)
• hydroxychloroquine+penicillamine: Severe (increases risk of haematological toxicity)
• hydroxychloroquine+agalsidase alfa: Unknown (decreases effects)
• hydroxychloroquine+agalsidase beta: Unknown (decreases exposure)
• hydroxychloroquine+oral cholera vaccine: Unknown (decreases efficacy)
• live vaccines+hydroxy carbamide: Unknown (increases risk of generalised infection (possibly life-threatening))
• lanthanum+hydroxychloroquine: Unknown (decreases absorption)
• macrolides+hydroxychloroquine: Unknown (increases risk of serious cardiovascular adverse effects)
• hydroxychloroquine+remdesivir: Unknown (decreases effects)

Pregnancy

Safety in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Use with caution. Hydroxychloroquine is excreted in breast milk, and effects on the infant are unknown.

Storage

Store in a cool, dry place, protected from light. Keep out of reach of children.

Formulations

• Tablets
• Oral solution

Indications

• Coloring agent in pharmaceuticals
• Improving the appearance of drug formulations
• Enhancing the identification of medications

Dosage

Children: Refer to specific formulation guidelines and product information for dosing details, as Opacode is used as an excipient and not administered directly.

Adults: Refer to specific formulation guidelines and product information for dosing details, as Opacode is used as an excipient and not administered directly.

Mechanism of action

The specific mechanism of action of Opacode is not well-defined as it primarily acts as an excipient rather than an active pharmaceutical ingredient. Its function is largely physical, influencing the aesthetic properties of drug formulations without pharmacological activity.

Pharmacodynamics

As an excipient, Opacode does not exhibit pharmacodynamic properties in the traditional sense. Its role is to provide color and opacity to drug products, which can aid in patient compliance by making medications easier to recognize. The pharmacodynamic impact of Opacode is limited to its contribution to the overall formulation.

Pharmacokinetics

Opacode is not absorbed systemically as it is used in solid dosage forms, where it remains in the gastrointestinal tract until excretion. Its pharmacokinetic profile is not applicable as it does not have therapeutic effects or bioavailability in the body.

Pregnancy

There is limited information on the safety of Opacode during pregnancy. It is advisable to use this drug only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

The effects of Opacode during breastfeeding are not well studied. Caution is recommended when administering to nursing mothers.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Emulsifying agent in topical formulations
• Solubilizing agent for poorly soluble drugs
• Stabilizer in oral and parenteral drug formulations

Dosage

Children: Refer to specific formulation guidelines and product information, as dosages can vary widely depending on the intended use.

Adults: Refer to specific formulation guidelines and product information, as dosages can vary widely depending on the intended use.

Mechanism of action

Polyoxylglycerides function by reducing the surface tension between different phases, such as oil and water, allowing for the formation and stabilization of emulsions. This mechanism facilitates the uniform distribution of active pharmaceutical ingredients within a formulation, enhancing bioavailability and therapeutic efficacy.

Pharmacodynamics

The pharmacodynamic effects of polyoxylglycerides are primarily related to their role as emulsifiers and solubilizers. They enhance the absorption of lipophilic drugs by promoting their dispersion in aqueous environments, leading to improved pharmacological effects. Additionally, their surfactant properties can influence the release profiles of drugs from solid dosage forms.

Pharmacokinetics

Polyoxylglycerides are generally not absorbed in significant amounts when administered orally or topically, as they primarily act locally at the site of application. They are metabolized through hydrolysis into glycerol and fatty acids, which are then further metabolized or excreted. The pharmacokinetic profile may vary depending on the specific formulation and route of administration.

Pregnancy

Polyoxylglycerides are generally considered safe for use during pregnancy, but it is advisable to consult a healthcare professional before use.

Breast-feeding

There is limited information on the excretion of polyoxylglycerides in human milk. Caution is advised and a healthcare professional should be consulted.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Dosage

Children: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Adults: Refer to specific drug formulations and product labels as purified substances can vary widely in their use and dosing.

Mechanism of action

The mechanism of action for purified compounds varies widely depending on the specific substance. Generally, purified drugs exert their effects by interacting with specific biological targets, such as receptors, enzymes, or ion channels, leading to a desired therapeutic effect. This interaction can involve binding to receptors to activate or inhibit signaling pathways, modulating enzymatic activity, or altering physiological processes.

Pharmacodynamics

Pharmacodynamics describes the effects of a drug on the body and the relationship between drug concentration and effect. For purified drugs, this can involve dose-response relationships and the time course of their action. The purified form often enhances potency and reduces variability in response among patients, which can lead to more predictable therapeutic outcomes. The overall effect is determined by the drug's affinity for its target, the efficacy of the drug-receptor interaction, and the downstream signaling pathways activated as a result of this interaction.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of a drug. For purified substances, absorption can be more efficient due to the absence of impurities that may affect solubility or stability. Distribution may also be enhanced, leading to higher bioavailability. Metabolism can be influenced by the structure of the purified compound, as it may be metabolized more readily by liver enzymes. Excretion typically occurs through the kidneys or liver, depending on the molecular characteristics of the purified drug.

Pregnancy

Consult with a healthcare professional, as the safety of purified forms of medications during pregnancy may vary depending on the specific substance.

Breast-feeding

Consult with a healthcare professional, as the safety of purified forms of medications during breastfeeding may vary depending on the specific substance.

Storage

Store in a cool, dry place, away from light and moisture, and keep out of reach of children.

Dosage

Children: Refer to the specific drug's dosing guidelines for children.

Adults: Refer to the specific drug's dosing guidelines for adults.

Pregnancy

Consult with a healthcare provider, as safety data may vary depending on the specific drug and its classification.

Breast-feeding

Consult with a healthcare provider, as safety data may vary depending on the specific drug and its classification.

Storage

Store in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Emulsifying agent in topical formulations
• Stabilizing agent in oral drug formulations
• Food industry applications as an emulsifier
• Cosmetic formulations

Dosage

Children: Refer to specific formulation guidelines for dosage recommendations.

Adults: Refer to specific formulation guidelines for dosage recommendations.

Mechanism of action

Sorbitan acts primarily as a surfactant and emulsifier. Its amphiphilic nature allows it to reduce the surface tension between oil and water, thereby facilitating the formation and stabilization of emulsions. The hydrophilic part of the sorbitan molecule interacts with water, while the lipophilic part interacts with oils, promoting the mixing of immiscible liquids.

Pharmacodynamics

As an emulsifier, sorbitan enhances the bioavailability of lipophilic drugs by aiding their dispersion in aqueous environments. This property is particularly valuable in formulations where uniform distribution of active ingredients is critical for efficacy. Sorbitan may also impact the release profiles of drugs from emulsified formulations, potentially affecting the onset of action.

Pharmacokinetics

Sorbitan is generally considered to be poorly absorbed when administered orally, leading to minimal systemic exposure. Its primary role is local, serving as an excipient in formulations rather than as an active therapeutic agent. Due to its emulsifying properties, it may enhance the solubility and absorption of other drugs in the gastrointestinal tract, but the absorption characteristics of sorbitan itself are limited. Metabolism and excretion details specific to sorbitan are not well-documented, as it typically functions in a non-systemic capacity.

Pregnancy

Sorbitan has not been well studied in pregnant women. Use during pregnancy should be based on a risk-benefit assessment.

Breast-feeding

Sorbitan is generally considered safe during breastfeeding, however, there is limited data available.

Storage

Store at room temperature, away from moisture and heat. Keep container tightly closed.

Formulations

• Sorbitan monooleate
• Sorbitan monostearate
• Sorbitan tristearate

Indications

• Constipation
• Diagnostic aid in colonoscopy preparation
• Management of hyperosmolality in various conditions

Dosage

Children: For children, the dosage should be determined based on age and condition, and it is advised to refer to the BNF for Children for specific dosing guidelines.

Adults: The typical dose for adults is 30 to 150 mL of sorbitol solution (70%) taken orally, as needed, usually before bedtime.

Mechanism of action

Sorbitol exerts its laxative effect by drawing water into the large intestine, thereby stimulating bowel movements. It acts as a hygroscopic agent, pulling water from tissues into the feces, which reflexively stimulates evacuation. In metabolic pathways, sorbitol is produced from glucose via aldose reductase and is converted to fructose by sorbitol dehydrogenase, with implications in diabetic complications such as retinopathy.

Pharmacodynamics

Sorbitol's laxative effect results from its osmotic properties, which increase the water content of the stool and soften it, facilitating easier passage. Additionally, sorbitol can induce apoptosis in certain cancer cell lines, indicating potential therapeutic implications beyond its laxative use. The modulation of intracellular signaling pathways through the regulation of proteins such as Bax and Bcl-2 suggests a complex role in cellular health and disease.

Pharmacokinetics

Sorbitol is poorly absorbed in the gastrointestinal tract, which contributes to its efficacy as a laxative. It is metabolized in the liver, primarily through the polyol pathway. The absorption and distribution of sorbitol are affected by its osmotic properties, leading to increased intestinal water retention. Its elimination is primarily via renal excretion, with minimal systemic absorption, thus reducing the risk of systemic side effects.

Adverse effects

• Diarrhea
• Abdominal cramps
• Nausea
• Vomiting
• Electrolyte imbalances

Precautions

• Use with caution in patients with renal impairment
• May exacerbate gastrointestinal conditions

Pregnancy

Sorbitol is generally considered safe during pregnancy, but should be used under medical supervision.

Breast-feeding

Sorbitol is excreted in breast milk in small amounts; consult a healthcare provider before use.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Oral solution
• Syrup

Dosage

Children: Refer to specific drug guidelines in the BNF for Children for appropriate dosing information.

Adults: Refer to specific drug guidelines in the BNF for appropriate dosing information.

Mechanism of action

The mechanism of action will vary significantly depending on the specific drug referred to as 'sufficient.' Generally, mechanisms of action may include receptor agonism or antagonism, enzyme inhibition, or modulation of signaling pathways within cells. Understanding the specific drug's pharmacodynamics is crucial for determining its therapeutic efficacy.

Pharmacodynamics

Pharmacodynamics involves the study of the biochemical and physiological effects of drugs and their mechanisms of action. It encompasses the interactions between drug molecules and target receptors, the resulting cellular responses, and the overall therapeutic effects observed in patients. The relationship between drug concentration and effect is fundamental to understanding drug efficacy and safety.

Pharmacokinetics

Pharmacokinetics describes how a drug is absorbed, distributed, metabolized, and excreted in the body. Key parameters include bioavailability, volume of distribution, clearance, and half-life. These factors influence dosing regimens and the timing of therapeutic effects. Individual patient characteristics, such as age, sex, organ function, and genetic factors, can also impact pharmacokinetic profiles.

Pregnancy

Consult with a healthcare provider before use. Insufficient data on safety.

Breast-feeding

Consult with a healthcare provider before use. Insufficient data on safety.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Orthopedic implants
• Dental implants
• Prosthetic devices
• Surgical instruments

Mechanism of action

Titanium does not have a specific mechanism of action as it is not a drug in the traditional sense. Instead, its biocompatibility allows it to integrate with biological tissues without eliciting significant immune responses, making it suitable for use in implants and prosthetic devices. The presence of titanium ions can influence biological processes, including cell proliferation and differentiation.

Pharmacodynamics

Titanium itself does not exhibit pharmacodynamics as it is not administered as a drug. Its interactions within biological systems are primarily mechanical and structural, providing support and stability in orthopedic and dental applications. The biocompatibility of titanium allows for favorable tissue integration and reduced rejection rates compared to other materials.

Pharmacokinetics

As titanium is not a pharmacological agent, traditional pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion do not apply. Titanium is typically utilized in solid forms, such as implants, where it remains localized and does not undergo metabolism or systemic circulation.

Pregnancy

There is limited data on the use of titanium during pregnancy. Consult a healthcare professional before use.

Breast-feeding

There is limited data on the excretion of titanium in breast milk. Consult a healthcare professional before use.

Storage

Store in a cool, dry place away from direct sunlight.

Mechanism of action

Enzalutamide is a competitive androgen receptor (AR) inhibitor that has a threefold inhibition on the androgen signaling pathway without significant AR agonist activity. It inhibits androgen binding to its receptor, androgen receptor nuclear translocation, and subsequent interaction with chromosomal DNA to upregulate oncogenes. Enzalutamide binds to the AR with 5 to 8-fold greater affinity than first-generation antiandrogens such as bicalutamide and only 2-3 fold reduced affinity than the natural ligand dihydrotestosterone. Molecular docking showed that enzalutamide binds to the ligand binding domain of the AR distinctive from that of bicalutamide.

Pharmacodynamics

Enzalutamide is a second-generation antiandrogen that blocks the activity of androgen and androgen receptor (AR) in prostate cancer. AR activity and prostate cancer progression are closely related due to the normal physiology of prostate cells, providing the rationale for androgen deprivation therapy (ADT). However, resistance will eventually arise after the commencement of ADT in 2-3 years due to the accumulation of mutations, including constitutively active mutation, AR overexpression, and changes in AR splicing variants. Enzalutamide was therefore designed to exploit these mutations. In vitro experiments in human prostate cancer cell line VCaP showed that enzalutamide can suppress cell growth and induce apoptosis while other antiandrogens like bicalutamide did not. Clinical trials on prostate cancer patients indicated that enzalutamide can lead to a decrease in serum PSA for at least 12 weeks, although this response can be short-lived and thus resulting in enzalutamide resistance. Patients receiving enzalutamide also had a 37% decreased in the risk of death compared to placebo.

Mechanism of action

Pro-oxidative effect of phenolic antioxidant (vitamin E) in combination with the initiators on human low-density lipoprotein is known. /It has been/ reported that oxidative stress induced by vitamin E in combination with the herbicide paraquat enhances structural chromosomal damage in cultured anuran leukocytes. In the present study, the phenolic antioxidant vitamin E-synthetic-analogue 2,6-di-tert-butyl-p-cresol (BHT) in combination with paraquat was found to enhance structural chromosomal damage in cultured Pelophylax (Rana) nigromaculatus leukocytes more than paraquat only and paraquat plus nicotinamido adenine dinucleotido phosphate served as positive control, although BHT only had no effect on induction of structural chromosomal damage. Paraquat plus BHT-enhanced structural chromosomal damage was inhibited by combination of the superoxide dismutase mimic Mn(III)tetrakis(1-methyl-4-pyridyl)porphyrin and the hydrogen peroxide scavenger catalase. In test based on reduction of paraquat cation, BHT was found to reduce paraquat cation chemically to paraquat monocation radical. These results suggest that BHT functions in chemically donating electron to paraquat and thereby induces an acute accumulation of reactive oxygen species, resulting in increase in chromosomal damage. Promotion of lung tumors in mice by the food additive butylated hydroxytoluene (BHT) is mediated by electrophilic metabolites produced in the target organ. Identifying the proteins alkylated by these quinone methides (QMs) is a necessary step in understanding the underlying mechanisms. Covalent adducts of the antioxidant enzymes peroxiredoxin 6 and Cu,Zn superoxide dismutase were detected previously in lung cytosols from BALB/c mice injected with BHT, and complimentary in vitro studies demonstrated that QM alkylation causes inactivation and enhances oxidative stress. In the present work, adducts of another protective enzyme, carbonyl reductase (CBR), were detected by Western blotting and mass spectrometry in mitochondria from lungs of mice one day after a single injection of BHT and throughout a 28-day period of weekly injections required to achieve tumor promotion. BHT treatment was accompanied by the accumulation of protein carbonyls in lung cytosol from sustained oxidative stress. Studies in vitro demonstrated that CBR activity in lung homogenates was susceptible to concentration- and time-dependent inhibition by QMs. Recombinant CBR underwent irreversible inhibition during QM exposure, and mass spectrometry was utilized to identify alkylation sites at Cys 51, Lys 17, Lys 189, Lys 201, His 28, and His 204. Except for Lys 17, all of these adducts were eliminated as a cause of enzyme inhibition either by chemical modification (cysteine) or site-directed mutagenesis (lysines and histidines). The data demonstrated that Lys 17 is the critical alkylation target, consistent with the role of this basic residue in NADPH binding. These data support the possibility that CBR inhibition occurs in BHT-treated mice, thereby compromising one pathway for inactivating lipid peroxidation products, particularly 4-oxo-2-nonenal. These data, in concert with previous evidence for the inactivation of antioxidant enzymes, provide a molecular basis to explain lung inflammation leading to tumor promotion in this two-stage model for pulmonary carcinogenesis.

Mechanism of action

When administered rectally, glycerin exerts a hygroscopic and/or local irritant action, drawing water from the tissues into the feces and reflexively stimulating evacuation. Glycerin decreases intraocular pressure by creating an osmotic gradient between the blood and intraocular fluid, causing fluid to move out of the aqueous and vitreous humors into the bloodstream. Glycerin (glycerol) and sorbitol are hyperosmotic laxatives. When administered rectally, glycerin and sorbitol exert a hygroscopic and/or local irritant action, drawing water from the tissues into the feces and reflexly stimulating evacuation. The extent to which the simple physical distention of the rectum and the hygroscopic and/or local irritant actions are responsible for the laxative effects of some of these drugs is not known. Only extremely high oral doses of sorbitol (25 g daily) or glycerin exert laxative action. /Glycerin/ decreases intraocular pressure by creating an osmotic gradient between the blood and intraocular fluid, causing fluid to move out of the aqueous and vitreous humors into the bloodstream. The physicochemical effects of a series of alkanols, alkanediols and glycerol on erythrocyte shape and hemolysis at 4 and 20 degrees C were examined. We calculated the dielectric constant of the incubation medium, Ds, and the dielectric constant of the erythrocyte membrane Dm in the presence of organic solutes. The ratio Ds/Dm = -38.48 at 20 degrees C defines the normal biconcave shape in a medium without hemolytic agents. A decrease in Ds/Dm favors externalization or internalization with consequent hemolysis. Alkanols and alkanediols convert biconcave erythrocytes into echinocytes, which is accompanied by an increase in the projected surface area. Glycerol converts biconcave erythrocytes into stomatocytes, which was accompanied by a marginal decrease in the projected surface area. Progressive externalization in alkanols and alkanediols or internalization in glycerol resulted in a decrease in the projected surface area and the formation of smooth spheres. The degree of shape change induced was related to the degree of hemolysis and the ratio Ds/Dm. A decrease in temperature reduced both the degree of shape change and hemolysis. .../Thus/ physicochemical toxicity may be a result of a temperature dependent hydrophobic interaction between the organic solutes and the membrane and is best interpreted by the ability of the solutes to change Ds and Dm.

Pharmacodynamics

Glycerin is commonly classified as an osmotic laxative but may act additionally or alternatively through its local irritant effects; it may also have lubricating and fecal softening actions. Glycerin suppositories usually work within 15 to 30 minutes.

Mechanism of action

Sorbitol exerts its laxative effect by drawing water into the large intestine, thereby stimulating bowel movements. ... Sorbitol exerts hygroscopic and/or local irritant action, drawing water from tissues into feces and reflexly stimulating evacuation. The polyol pathway consists of two enzymes aldose reductase (AR) and sorbitol dehydrogenase (SDH); the former is the first enzyme in the polyol pathway, that catalyzes the reduction of glucose to sorbitol, the latter is the second one, that converts sorbitol to fructose using by NAD(+) as a cofactor. ... SDH activity, the second step in the polyol pathway, might make a greater contribution to the etiology of diabetic retinopathy than does the first step involving AR. /This paper proposes/ a novel hypothesis that polymorphisms of SDH gene may be correlated with SDH gene expression levels in diabetic retinas, thus being a valuable genetic marker for diabetic retinopathy. It has been reported that sorbitol induces apoptosis in several cancer cell lines. ... In /this/ study, the intracellular signaling pathways of sorbitol-induced apoptosis in human K562 cells were investigated using both morphological analysis and DNA fragmentation technique. In this study, we demonstrated that sorbitol-induced apoptosis in human K562 cells is a concentration- and time-dependent manner. This sorbitol-induced apoptosis in human K562 cells was also accompanied by the up-regulation of Bax, and down-regulation of p-Bcl-2, but no effect on the levels of Bcl-X(L). Moreover, the sorbitol treatment resulted in a significant reduction of mitochondria membrane potential, increase in the release of mitochondrial cytochrome c (cyt c), and activation of caspase 3. Furthermore, treatment with caspase 3 inhibitor (z-DEVD-fmk) was capable of preventing the sorbitol-induced caspase 3 activity and cell death. These results clearly demonstrate that the induction of apoptosis by sorbitol involves multiple cellular/molecular pathways and strongly suggest that pro- and anti-apoptotic Bcl-2 family proteins, mitochondrial membrane potential, mitochondrial cyt c, and caspase 3, they all participate in sorbitol-induced apoptotic process in human K562 cells. Chronic diabetic complications, in particular, nephropathy, peripheral and autonomic neuropathy, "diabetic foot," retinopathy, and cardiovascular disease, remain the major cause of morbidity and mortality in patients with diabetes mellitus. Growing evidence indicates that both increased activity of the sorbitol pathway of glucose metabolism and enhanced oxidative stress are the leading factors in the pathogenesis of diabetic complications. The relation between the two mechanisms remains the area of controversy. One group has reported that increased sorbitol pathway activity has a protective rather than detrimental role in complication-prone tissues because the pathway detoxifies toxic lipid peroxidation products. Others put forward a so-called "unifying hypothesis" suggesting that activation of several major pathways implicated in diabetic complications (eg, sorbitol pathway) occurs due to increased production of superoxide anion radicals in mitochondria and resulting poly(ADP-ribose) polymerase activation. This review (a) presents findings supporting a key role for the sorbitol pathway in oxidative stress and oxidative stress-initiated downstream mechanisms of diabetic complications, and (b) summarizes experimental evidence against a detoxifying role of the sorbitol pathway, as well as the "unifying concept."